8-K: Curaleaf Boosts Aurora Bid, Extends Deadline

Curaleaf Holdings, Inc. has enhanced its offer to acquire Aurora Cannabis Inc., increasing the total implied consideration and extending the offer's expiry date, while Aurora's management continues to resist engagement.

Summary

• Curaleaf Holdings, Inc. has filed a Notice of Variation, Change and Extension to its offer to purchase all outstanding common shares of Aurora Cannabis Inc.
• The offer has been enhanced with increased consideration and an extended expiry time.
• The new offer includes US$1.00 in cash and 0.4013 of a Curaleaf subordinate voting share per Aurora common share, subject to a maximum value of US$6.00 per share.
• The expiry time for the offer has been extended to 11:59 p.m. (Mountain Time) on December 4, 2026.
• Aurora's management has not engaged in substantive discussions and has recommended shareholders reject the offer.
• Curaleaf has filed the necessary documentation with U.S. and Canadian securities regulatory authorities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as Curaleaf has increased its offer and extended the deadline, indicating continued commitment despite Aurora's lack of engagement. However, the lack of due diligence access and Aurora's continued resistance temper the overall sentiment.

Positives

• Curaleaf has increased the total implied consideration for Aurora shares by 25% to US$5.00 per share.
• The cash component of the offer has been increased by 33% to US$1.00 per share, providing immediate liquidity.
• The share consideration has been increased to 0.4013 Curaleaf shares per Aurora share.
• The maximum consideration per share (Cap Price) has been increased by 20% to US$6.00.
• The offer represents a significant premium of 86% to Aurora's unaffected share price (30-day VWAP before the initial offer).
• Excluding Aurora's cash and equivalents, the offer represents a 217% premium to Aurora's ex-cash share price.
• The combination is projected to create a global cannabis leader with over US$1.5 billion in LTM revenue and nearly US$350 million in LTM Adjusted EBITDA.
• Expected annual cost synergies of at least US$40 million are anticipated.

Negatives

• Aurora Cannabis Inc.'s management and board have refused to engage in substantive discussions and have recommended shareholders reject the offer.
• Curaleaf has not been granted access to Aurora's non-public information for due diligence.
• Aurora has continued to issue shares under its at-the-market program at prices below the offer's implied value, diluting existing shareholders.
• Curaleaf had to file an application to halt Aurora's ATM issuances, citing them as a defensive tactic.
• The offer is unsolicited, and Aurora's board has advised against it.

Risks

• The offer is subject to conditions, including the tender of more than 50% of Aurora's outstanding common shares (excluding those held by Curaleaf) and the tender of at least 66% on a fully diluted basis (which Curaleaf may waive).
• There is a risk that anticipated synergies and other benefits of the offer may not be realized.
• Changes in general economic conditions, operating conditions, foreign exchange and interest rates could adversely affect the combined company.
• New or changing laws (domestic and foreign) could impact operations.
• The risk of failure to satisfy the conditions to the offer.
• Curaleaf has been unable to independently verify the accuracy and completeness of Aurora's public information.
• The offer is subject to regulatory approvals.
• Company Shareholders who do not deposit their shares may have rights of dissent in the event of a Compulsory Acquisition or Subsequent Acquisition Transaction.

Future Outlook

The filing indicates that the combination of Curaleaf and Aurora is expected to create a global cannabis leader with significant scale, diversification, and enhanced liquidity, leading to a lower cost of capital and greater opportunities for shareholders. Curaleaf anticipates realizing at least US$40 million in annual cost synergies. The pro forma financial statements provide an outlook on the combined entity's financial position and results of operations.

Management Comments

• "This increased offer reflects careful consideration and shareholder input, demonstrating our continued commitment to reaching a successful outcome."
• "Importantly, we are enhancing our proposal despite Aurora's refusal to engage and provide access to customary due diligence."
• "We view this as a significant good-faith step that demonstrates our conviction in the merits of a combination and the value creation opportunity it represents."
• "We have demonstrated our willingness to act in the best interest of shareholders."
• "While this is not how we would expect to engage in a sale process, we are prepared to act because we believe strongly in the value creation opportunity."
• "Importantly, if Aurora is providing diligence access to other parties, shareholders deserve a fair and open process that includes Curaleaf."
• "A combination of Curaleaf and Aurora would create the global cannabis leader, with operations across 17 countries, more than US$1.5 billion of last-twelve-month (LTM) revenue, nearly US$350 million of LTM Adjusted EBITDA and at least US$40 million of expected annual cost synergies."

Industry Context

StockSavvy.ai notes that this enhanced offer occurs within a consolidating global cannabis market. Curaleaf's move to increase its bid and extend the deadline, despite Aurora's resistance, highlights the strategic importance Curaleaf places on acquiring Aurora's international footprint and market position. Aurora's continued lack of engagement and reliance on its own standalone prospects, while issuing shares under an ATM program, is a common defensive tactic observed in such situations.

Comparison to Industry Standards

• The offer's premium of 86% to Aurora's unaffected share price is substantial and aligns with premiums seen in other significant M&A transactions within the cannabis sector, particularly those involving companies with international reach.
• The projected combined LTM revenue of over US$1.5 billion and LTM Adjusted EBITDA of nearly US$350 million would position the merged entity as a dominant global player, surpassing many current industry leaders in scale.
• The projected US$40 million in annual cost synergies is a standard target for mergers of this nature, aiming to leverage operational efficiencies and reduce overlapping functions.
• The structure of the offer, combining cash and stock, is typical for large-scale acquisitions, providing a mix of immediate value and participation in future growth.

Legal Proceedings

• Curaleaf filed an application with the Alberta Securities Commission seeking to halt further issuances under Aurora's ATM Program, alleging it was an improper defensive tactic.

Stakeholder Impact

• Shareholders of Aurora Cannabis Inc. are directly impacted by the enhanced offer, with increased consideration and an extended timeline to make a decision.
• Curaleaf shareholders may see increased share dilution if the offer is successful, but also potential long-term benefits from the acquisition of Aurora.
• Employees of both companies may face uncertainty regarding future roles and integration following a potential combination.
• Creditors of Aurora may be impacted by the change in ownership and the combined company's financial structure.

Next Steps

• Aurora shareholders are urged to read the Notice of Variation, Change and Extension and other relevant filings.
• Aurora shareholders are advised to consult their investment advisors regarding the offer.
• Curaleaf will continue to pursue the offer and engage with Aurora shareholders.
• Curaleaf remains open to engaging in good-faith discussions with Aurora's management and board.
• Aurora shareholders who have validly deposited shares do not need to take further action.
• Aurora shareholders who have not yet deposited shares must follow the specified procedures to accept the offer.
• Curaleaf will file further amendments to its registration statements and tender offer statements with the SEC.

Key Dates

Recommendation

While Curaleaf has significantly enhanced its offer and extended the deadline, Aurora's management continues to resist engagement and recommend rejection. The offer presents a substantial premium, but the lack of due diligence and Aurora's stated belief in its standalone prospects create uncertainty. For Aurora shareholders, holding allows for potential further negotiation or a clearer view of Aurora's standalone performance versus the offer's value. For Curaleaf shareholders, the increased offer represents a higher cost for the acquisition, and the success is not guaranteed.

Keywords

Curaleaf, Aurora Cannabis, Takeover Bid, Offer Enhancement, Cannabis Industry, Merger, Acquisition, Securities Law